Evidence has shown benefits of single-strain probiotics for Helicobacter pylori eradication.
Dr Ahmad Shavakhi from Iran investigated the effects of adding a multistrain probiotic compound on bismuth-containing quadruple therapy for H. pylori infection.
The team randomized adult patients with peptic ulcer disease and confirmed H. pylori infection to receive bismuth-containing quadruple therapy plus a probiotic compound or placebo for 2 weeks.
The probiotic compound contained 7 bacterial species including Lactobacillus and Bifidobacterium strains and Streptococcus thermophiles.
Eradication of H. pylori was assessed 4 weeks after medication by 13C urea breath test.
|H. pylori was eradicated in 82% of the probiotic vs 84% of the placebo group|
Other outcomes were dyspepsia symptoms, therapy-related adverse effects, and patient's tolerance.
The team reported that 84 patients in the probiotic, and 86 in the placebo group completed the trial.
The research team found that with per-protocol analysis, H. pylori was eradicated in 82% of the probiotic, and 85% of the placebo group.
Symptoms were significantly improved with similar trends in both groups.
Regarding the adverse effects, diarrhea was less frequent, while abdominal pain was more frequent in the probiotic group.
The 2 groups were similar in treatment tolerance.
Dr Shavakhi's team comments, "Overall, our studied multistrain probiotic compound has no beneficial effects in the treatment of H. pylori infection."
"It might be related to the low dosage of our probiotic regimen and/or high frequency of upper gastrointestinal adverse effects which in turn could decrease the eradication efficacy."